Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
19 05 2021
Historique:
received: 30 12 2020
accepted: 23 03 2021
pubmed: 31 3 2021
medline: 24 6 2021
entrez: 30 3 2021
Statut: epublish

Résumé

LamPORE is a novel diagnostic platform for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA combining loop-mediated isothermal amplification with nanopore sequencing, which could potentially be used to analyze thousands of samples per day on a single instrument. We evaluated the performance of LamPORE against reverse transcriptase PCR (RT-PCR) using RNA extracted from spiked respiratory samples and stored nose and throat swabs collected at two UK hospitals. The limit of detection of LamPORE was 10 genome copies/μl of extracted RNA, which is above the limit achievable by RT-PCR, but was not associated with a significant reduction of sensitivity in clinical samples. Positive clinical specimens came mostly from patients with acute symptomatic infection, and among them, LamPORE had a diagnostic sensitivity of 99.1% (226/228; 95% confidence interval [CI], 96.9% to 99.9%). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (278/279; 98.0% to 100.0%). Overall, 1.4% (7/514; 0.5% to 2.9%) of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8% (478/494; 94.8% to 98.1%). LamPORE has a similar performance as RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients and offers a promising approach to high-throughput testing.

Identifiants

pubmed: 33782112
pii: JCM.03271-20
doi: 10.1128/JCM.03271-20
pmc: PMC8315953
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Peto et al.

Références

J Biochem Biophys Methods. 2007 Apr 10;70(3):499-501
pubmed: 17011631
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
J Infect. 2021 Jan;82(1):159-198
pubmed: 32474037
J Infect. 2021 Jan;82(1):117-125
pubmed: 33271166
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
J Clin Virol. 2020 Nov;132:104616
pubmed: 32891938
ACS Cent Sci. 2021 Feb 24;7(2):307-317
pubmed: 33649735
R Soc Open Sci. 2020 Jun 24;7(6):200915
pubmed: 32742705
Anal Chem. 2007 Aug 1;79(15):5608-13
pubmed: 17579496
Biotechniques. 2020 Sep;69(3):178-185
pubmed: 32635743
Clin Infect Dis. 2020 Dec 03;:
pubmed: 33270107
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32719001
Infect Dis Ther. 2020 Sep;9(3):573-586
pubmed: 32725536
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387

Auteurs

Leon Peto (L)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom leon.peto@ndm.ox.ac.uk.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Gillian Rodger (G)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Daniel P Carter (DP)

Public Health England, National Infection Service, Salisbury, United Kingdom.

Karen L Osman (KL)

Public Health England, National Infection Service, Salisbury, United Kingdom.

Mehmet Yavuz (M)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Katie Johnson (K)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Mohammad Raza (M)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Matthew D Parker (MD)

Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, University of Sheffield, Sheffield, United Kingdom.

Matthew D Wyles (MD)

Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, University of Sheffield, Sheffield, United Kingdom.

Monique Andersson (M)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Anita Justice (A)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Alison Vaughan (A)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Sarah Hoosdally (S)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Nicole Stoesser (N)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Philippa C Matthews (PC)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

David W Eyre (DW)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Timothy E A Peto (TEA)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Miles W Carroll (MW)

Public Health England, National Infection Service, Salisbury, United Kingdom.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Thushan I de Silva (TI)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
The Florey Institute for Host-Pathogen Interactions, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.

Derrick W Crook (DW)

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford in partnership with Public Health England, Oxford, United Kingdom.

Cariad M Evans (CM)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Steven T Pullan (ST)

Public Health England, National Infection Service, Salisbury, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH